Nõu E, Steinholtz L, Bergh J, Nilsson K, Påhlman S
Department of Lung Medicine, Uppsala University, Sweden.
Cancer. 1990 Mar 15;65(6):1380-5. doi: 10.1002/1097-0142(19900315)65:6<1380::aid-cncr2820650622>3.0.co;2-u.
The value of measurement of serum neuron-specific enolase (NSE) as a follow-up marker was investigated in 88 patients with small cell bronchial carcinoma. Of these, 42 had extensive disease and 46 had limited disease. The mean NSE levels before treatment, at response, and at recurrence in extensive disease were 107, 10, and 52 ng/ml, respectively, and the corresponding levels in limited disease were 35, 10, and 19 ng/ml, respectively. All differences were statistically clearly significant. However, the sensitivity of NSE in serum at response was 66% and at recurrence, 38%. The predictive value of an NSE decrease at response was 88%, and at recurrence, 72%. It is concluded that NSE changes during follow-up support the evaluation of the outcome but cannot be used as a monitoring agent in an individual patient.
对88例小细胞支气管癌患者血清神经元特异性烯醇化酶（NSE）作为随访标志物的价值进行了研究。其中42例为广泛期疾病，46例为局限期疾病。广泛期疾病患者治疗前、缓解时和复发时的平均NSE水平分别为107、10和52 ng/ml，局限期疾病患者的相应水平分别为35、10和19 ng/ml。所有差异均具有明显统计学意义。然而，缓解时血清NSE的敏感性为66%，复发时为38%。缓解时NSE下降的预测价值为88%，复发时为72%。结论是，随访期间NSE的变化有助于评估预后，但不能作为个体患者的监测指标。
